Abstract: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of mixed anxiety-depression disorders.

Abstract: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of all mood disorders, adaptation disorders or mixed anxiety-depression disorders.

Abstract: A pharmaceutical composition containing a compound (a) selected from 1-(2-naphth-2-ylethyl)-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropryidine and a 4-substituted 1-phenylalkyl-1,2,3,6-tetrahydropyridine in combination with a compound (b) active in the symptomatic treatment of dementia of the Alzheimer type (DAT), especially an acetylcholinesterase inhibitor, for the complete treatment of DAT.

Abstract: The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a ?3-adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.

Abstract: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of all mood disorders, adaptation disorders or mixed anxiety-depression disorders.

Abstract: The present invention relates to the use of saredutant and of its pharmaceutically acceptable salts for the treatment or prevention of adaptation disorders, bipolar disorders, and dysthymic disorders.

Abstract: A pharmaceutical composition containing a compound (a) selected from 1-(2-naphth-2-ylethyl)-4-(3-trifluoro-methylphenyl)-1,2,3,6-tetrahydropryidine and a 4-substituted 1-phenylalkyl-1,2,3,6-tetrahydropyridine in combination with a compound (b) active in the symptomatic treatment of dementia of the Alzheimer type (DAT), especially an acetyicholinesterase inhibitor, for the complete treatment of DAT.

Abstract: The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a &bgr;3-adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.

Abstract: The invention relates to a method for the treatment of mood disorders utilizing osanetant or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a &bgr;3-adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.

Abstract: The invention relates to the use of NK.sub.1 receptor antagonists for the preparation of drugs with a cardioregulatory action, intended in particular for controlling heart rate disorders and cardiac dysrhythtmia.

Abstract: The present invention concerns the use of 4-amino-1-(2-pyridyl)piperidines of general formula (I') ##STR1## wherein R' represents hydrogen, a halogen atom, a methyl, methylthio, trifluoromethyl, trifluoromethylthio, (C.sub.1 -C.sub.3)alkoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, or phenoxy group optionally substituted with a halogen atom, a trifluoromethyl, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.3)alkylthio, or cyano group, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of those conditions deriving from disorders of the serotoninergic systems wherein a serotoninergic action selectively mediated by the 5-HT.sub.3 receptors is required, e.g. affective disorders, anxiety, psychotic troubles, constipation.

Abstract: A compound of formula ##STR1## and its acid addition salts are useful in the treatment of sexual dysfunctions in male mammals.

Abstract: Compounds of the formula ##STR1## in which: Z represents a halogen or a cyano, acetyl, trifluoroacetyl, nitro, C.sub.1 -C.sub.4 alkylthio, carboxyl, phosphono, dialkoxyphosphonyl or alkoxycarbonyl group, the alkylthio and alkoxy groups containing from 1 to 3 carbon atoms;R.sub.1 denotes a hydroxyl group and R.sub.2 represents hydrogen, or R.sub.1 and R.sub.2 taken together form an additional bond between the carbon atoms by which they are carried; andR.sub.3 representsa group NH--X--R.sub.4, in which X denotes a direct bond or an SO.sub.2 group and R.sub.4 represents a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 Alkyl group;a group --S--R.sub.5, in which R.sub.5 represents a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.

Abstract: Compounds of the formula ##STR1## in which: Z represents a halogen or a cyano, acetyl, trifluoroacetyl, nitro, C.sub.1 -C.sub.4 alkylthio, carboxyl, phosphono, dialkoxyphosphonyl or alkoxycarbonyl group, the alkylthio and alkoxy groups containing from 1 to 3 carbon atoms;R.sub.1 denotes a hydroxyl group and R.sub.2 represents hydrogen, or R.sub.1 and R.sub.2 taken together form an additional bond between the carbon atoms by which they are carried; andR.sub.3 representsa group NH--X--R.sub.4, in which X denotes a direct bond or an SO.sub.2 group and R.sub.4 represents a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 alkyl group;a group --S--R.sub.5, in which R.sub.5 represents a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.

Abstract: A method of treatment of depressive states which comprises administering in mammals in need thereof an effective amount of a compound ##STR1## R.sub.1 represents hydrogen, a halogen atom, a cyano group a nitro group, an acetyl group or a trifluoromethyl group;R.sub.2 represents a hydroxyl group, in which case R.sub.3 represents a hydrogen atom, or R.sub.2 and R.sub.3 taken together represent an additional bond between the carbon atoms by which they are carried; andR.sub.4 represents a 2-oxopyrrolidin-1-yl or 2-oxopiperid-1-yl group or a heterocyclic group selected from 1H-pyrid-2-on-1-yl, 1H-pyridazin-6-on-1-yl, 1H-pyrimidin-2-on-1-yl, 1H-pyrimidin-6-on-1-yl, 1H-pyrazin-2-on-1-yl and 1H-thiopyrid-2-on-1-yl groups which are unsubstituted or monosubstituted or disubstituted by a C.sub.1 -C.sub.4 alkyl group, a halogen atom or a hydroxyl, nitro, amino or carboxyl group and the pharmaceutically acceptable salts thereof.

Abstract: A method of treatment of anxiety and depression in mammals is described which comprises administering to a mammal in need thereof an effective amount of a trifluoromethylphenyl-tetrahydropyridine derivative of formula I ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene chain and R is selected from the group consisting of cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, pyridyl, 1-oxide-pyridyl and naphthyl, or of a pharmaceutically acceptable salt thereof.